Adkins D et al (2019) Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial. Lancet Oncol 20(9):1295–1305

Article  CAS  PubMed  Google Scholar 

Adotévi O et al (2023) Safety, immunogenicity, and 1-year efficacy of universal cancer peptide-based vaccine in patients with refractory advanced non-small-cell lung cancer: a phase Ib/phase IIa De-Escalation Study. J Clin Oncol 41(2):373–384

Article  PubMed  Google Scholar 

Akhatova A et al (2022) Prophylactic human papillomavirus vaccination: from the origin to the current state. Vaccines 10(11):1912

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alavi M, Hamidi M (2019) Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles. Drug Metab Pers Ther. https://doi.org/10.1515/dmpt-2018-0032

Article  PubMed  Google Scholar 

Alcaniz Boada E et al (2023) Agreement between L1 and E6/E7-based assays for detection of high-risk HPV in cervical, oropharyngeal and penile cancers. J Clin Pathol 76(7):467–473

Article  PubMed  Google Scholar 

Allahyari M, Mohit E (2016) Peptide/protein vaccine delivery system based on PLGA particles. Hum Vaccin Immunother 12(3):806–828

Article  PubMed  Google Scholar 

Amreddy N et al (2018) Recent advances in nanoparticle-based cancer drug and gene delivery. Adv Cancer Res 137:115–170

Article  CAS  PubMed  Google Scholar 

Anasir MI, Poh CL (2019) Advances in antigenic peptide-based vaccine and neutralizing antibodies against viruses causing hand, foot, and mouth disease. Int J Mol Sci 20(6):1256

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anderson TC et al (2022) Use of recombinant zoster vaccine in immunocompromised adults aged ≥19 years: recommendations of the advisory committee on immunization practices—United States, 2022. MMWR Morb Mortal Wkly Rep 71(3):80–84

Article  CAS  PubMed  PubMed Central  Google Scholar 

Araldi RP et al (2018) The human papillomavirus (HPV)-related cancer biology: an overview. Biomed Pharmacother 106:1537–1556

Article  CAS  PubMed  Google Scholar 

Badrinath S et al (2022) A vaccine targeting resistant tumours by dual T cell plus NK cell attack. Nature 606(7916):992–998

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baindara P, Mandal SM (2019) Antimicrobial peptides and vaccine development to control multi-drug resistant bacteria. Protein Pept Lett 26(5):324–331

Article  CAS  PubMed  Google Scholar 

Balasubramaniam SD et al (2019) Key molecular events in cervical cancer development. Medicina (kaunas) 55(7):384

Article  PubMed  Google Scholar 

Bartlett S, Skwarczynski M, Toth I (2020) Lipids as activators of innate immunity in peptide vaccine delivery. Curr Med Chem 27(17):2887–2901

Article  CAS  PubMed  Google Scholar 

Bassani-Sternberg M et al (2019) A phase Ib study of the combination of personalized autologous dendritic cell vaccine, aspirin, and standard of care adjuvant chemotherapy followed by Nivolumab for resected pancreatic adenocarcinoma-a proof of antigen discovery feasibility in three patients. Front Immunol 10:1832

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bauer DL et al (2023) The adjuvant combination of dmLT and monophosphoryl lipid a activates the canonical, nonpyroptotic NLRP3 inflammasome in dendritic cells and significantly interacts to expand antigen-specific CD4 T cells. J Immunol 210(10):1519–1530

Article  CAS  PubMed  Google Scholar 

Bergman H et al (2019) Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD013479

Article  PubMed  PubMed Central  Google Scholar 

Boudreau CM et al (2020) Selective induction of antibody effector functional responses using MF59-adjuvanted vaccination. J Clin Invest 130(2):662–672

Article  CAS  PubMed  Google Scholar 

Bravo L et al (2022) Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. Lancet 399(10323):461–472

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bruni L et al (2021) HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. Prev Med 144:106399

Article  PubMed  Google Scholar 

Coleman HN et al (2016) Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination. Cancer Immunol Immunother 65(5):563–573

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coleman RL et al (2021) Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 22(5):609–619

Article  CAS  PubMed  Google Scholar 

Common Ingredients in FDA-Approved Vaccines (2024). https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/common-ingredients-fda-approved-vaccines

Crosbie EJ et al (2013) Human papillomavirus and cervical cancer. Lancet 382(9895):889–899

Article  PubMed  Google Scholar 

D’Alicandro V et al (2019) Role of genetic variations on MHC class I antigen-processing genes in human cancer and viral-mediated diseases. Mol Immunol 113:11–15

Article  PubMed  Google Scholar 

D’Amico C et al (2021) Development of vaccine formulations: past, present, and future. Drug Deliv Transl Res 11(2):353–372

Article  PubMed  PubMed Central  Google Scholar 

Danielsson R, Eriksson H (2021) Aluminium adjuvants in vaccines—a way to modulate the immune response. Semin Cell Dev Biol 115:3–9

Article  CAS  PubMed  Google Scholar 

Della Fera AN et al (2021) Persistent human papillomavirus infection. Viruses 13(2):321

Article  CAS  PubMed  PubMed Central  Google Scholar 

Firdaus FZ, Skwarczynski M, Toth I (2022) Developments in vaccine adjuvants. Methods Mol Biol 2412:145–178

Article  CAS  PubMed  Google Scholar 

Giannone G et al (2022) HPV vaccination and HPV-related malignancies: impact, strategies and optimizations toward global immunization coverage. Cancer Treat Rev 111:102467

Article  PubMed  Google Scholar 

Girndt M et al (2022) Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: results of a randomized, multicenter phase 3 study. Hum Vaccin Immunother 18(6):2136912

Article  PubMed  PubMed Central  Google Scholar 

Godi A et al (2019) Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine. Vaccine 37(18):2455–2462

Article  CAS